Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer

Journal of Clinical Oncology

Volumn 14, Issue 4, 1996, Pages 1185-1191

  Gelmon, K A ^a   O'Reilly, S E ^a   Tolcher, A W ^a   Campbell, C ^a   Bryce, C ^a   Ragaz, J ^a   Coppin, C ^a   Plenderleith, I H ^a   Ayers, D ^a   McDermott, B ^a   Nakashima, L ^a   Healey, D ^a   Onetto, N ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; ONDANSETRON; PACLITAXEL;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE PAIN; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MAXIMUM ALLOWABLE CONCENTRATION; MYALGIA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THORAX PAIN;

EID: 9244223030     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.4.1185     Document Type: Article

References (30)

1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer: Hormonal, cytotoxic and immunotherapy. Lancet 330:1-15, 71-85, 1992
2. Henderson IC: Chemotherapy of advanced disease, in Harris AL Jr, Henderson IC, Hellman S, et al (eds): Breast Disease. Philadelphia, PA, Lippincott, 1987, pp 428-479
3. Horwitz SB, Cohen D, Rao S, et al: Taxol: Mechanisms of action and resistance. J Natl Cancer Inst 15:15-21, 1993
4. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol: An active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
5. Seidman AD, Reichan BS, Crown JPA, et al: Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 13:1152-1159, 1995
6. Reichman BS, Seidman AD, Crown JPA, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
7. Gelmon K, Nabholtz JM, Bontenbal M, et al: Randomised trial of two doses of paclitaxel in metastatic breast cancer after failure of standard therapy. Ann Oncol 5:483, 1994 (suppl 5; abstr 493)
8. Holmes FA, Newman RA, Madden T, et al: Schedule dependent pharmacokinetics in a phase 1 trial of Taxol and doxorubicin as initial chemotherapy for metastatic breast cancer. Ann Oncol 5:489, 1994 (suppl 5)
9. Sledge G, Robert N, Sparano J, et al: Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: The Eastern Cooperative Oncology Group experience. Semin Oncol 21:15-18, 1994 (suppl 8)
10. O'Shaughnessy JA, Fisherman JS, Cowan KH: Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer. Semin Oncol 21:19-23, 1994 (suppl 8)
11. Gianni L, Straneo M, Capri G, et al: Optimal dose and sequence finding study of paclitaxel (P) by 3 h infusion combined with bolus doxorubicin in untreated metastatic breast cancer patients. Proc Am Soc Clin Oncol 13:74, 1994 (abstr 97)
12. Tolcher A, Cowan K, Riley J, et al: Phase I study of paclitaxel and cyclophosphamide and G-CSF in metastatic breast cancer. Proc Am Soc Clin Oncol 13:73, 1994 (abstr 93)
13. Rigas J, Fennelly D, Show V, et al: Phase I study of sequential edatrexate followed by paclitaxel: A design based on in vitro synergy. Ann Oncol 5:490, 1994 (suppl 5; abstr 490)
14. Swenerton K, Eisenhauer E, Ten Bokkel Huinink W, et al: Taxol in relapsed ovarian cancer; High vs low dose and short vs long infusion: A European-Canadian study coordinated by the NCI Canada Clinical Trials Group. Proc Am Soc Clin Oncol 12:286, 1993 (abstr)
15. Kolaric K, Roth: Phase II clinical trial of cis-dichlordiamine platinum (cis-DDP) for antiumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 11:108-112, 1983
16. Mechl Z, Sopova B: CAP (cyclophosphamide, Adriamycin, cisplatinum) in the treatment of advanced breast cancer. Neoplasma 31:431-435, 1984
17. Sledge GW, Loehrer PJ, Roth BJ, et al: Cisplatin as first line therapy for metastatic breast cancer. J Clin Oncol 6:1811-1814, 1988
18. Smith IE, Talbot DC: Cisplatin and its analogues in the treatment of advanced breast cancer: A review. Br J Cancer 65:787-793, 1992
19. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New Engl J Med 334:1-6, 1996
20. Scanlon KJ, NeeDels C: Biochemical basis for cisplatinum and 5-fluorouracil synergism in human tumours. Proc Am Soc Clin Oncol 27:291, 1986 (abstr)
21. Zupi G, Greco C, Sacchi A, et al: Etoposide prior to cisdeamminedichloroplatinum in combination chemotherapy in vitro and in vivo studies. Eur J Cancer Clin Oncol 21:1501-1506, 1985
22. Durand RE, Goldie JH: Interaction of etoposide and cisplatin in an in vitro tumour model. Cancer Treat Rep 71:673-679, 1987
23. Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequences of Taxol and cisplatin: A phase 1 and pharmacologic study. J Clin Oncol 9:1692-1703, 1991
24. Miller AB, Hoogstraten B, Straquet M, et al: Reporting results of cancer treatment. Cancer 147:207-214, 1981
25. Gelmon K, Nabholtz JM, Bontenbal M, et al: Randomised trial of two doses of paclitaxel in metastatic breast cancer after failure of standard therapy. Ann Oncol 5:493, 1994 (suppl 5; abstr 493)
26. Postma TJ, Vermerken JB, Liefting AJM, et al: Paclitaxel-induced neuropathy. Ann Oncol 6:489-501, 1995
27. Perez T, Sulkes A, Chollet P, et al: A multicentred randomized study of two schedules of paclitaxel in patients with advanced breast cancer. Eur J Cancer 31A:575, 1995 (suppl 5; abstr 345)
28. Frazein A, Wasserheit C, Hochster H, et al: High rate of peripheral neuropathy may limit paclitaxel (T) and cisplatin (DDP) combination in women with advanced breast cancer (BC). Proc Am Soc Clin Oncol 14:145, 1995 (abstr)
29. Langer CJ, Leighton J, Comis R, et al: Paclitaxel (Taxol) and carboplatin (CBDCA) in advanced non-small cell lung cancer (NSCLC): Toxicity, response and survival update. Proc Am Soc Clin Oncol 14:1080, 1995 (abstr)
30. Bookman MA, McGuire WP, Kilpatrick D, et al: Phase 1 Gynecologic Oncology Group (GOG) study of 3H and 24 H paclitaxel with carboplatin as initial therapy for advanced epithelial ovarian cancer (OvCa). Proc Am Soc Clin Oncol 14:755, 1995 (abstr)